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Abstract 27 
Using an autoencoder-based analysis to classify genomes of SARS-CoV-2 28 
coronaviruses, we found a cluster consisting only of a specific genotype 29 
with two mutations in the helicase. This virus genotype, called C-type 30 
SARS-CoV-2, was almost exclusively prevalent in the United States from 31 
March to July 2020. This type of virus, characterized by a pair of the 32 
C17747T (P504L) and A17858G (Y541C) mutations on the nsp13 gene, had 33 
never been highly prevalent at any other time or in any other part of the 34 
world. In the U.S., Washington State was the center of the epidemic, and 35 
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the C-type viruses, along with the viruses with wild-type helicase, seemed 36 
to have aroused the pandemic. In Washington State, USA, the CoViD-19 37 
epidemic during the first two months of the year, starting at the end of 38 
February 2020, was mainly caused by the type-C virus. During this period, 39 
the infection spread rapidly; from May onwards, the number of viruses 40 
with wild-type helicases became higher than that of type-C viruses, and 41 
no type-C viruses have been collected since early July. The involvement 42 
of the helicase in this COVID-19 disease was discussed. 43 
 44 
Introduction 45 
Coronaviruses have had a major impact on human society since the 2002–2003 SARS 46 
epidemic (Coronaviridae Study Group of the International Committee on Taxonomy of 47 
Viruses. 2020). With the exception of influenza, there are few other viral infections that 48 
have been so prevalent, and it is important to elucidate the characteristics of viruses (Hua 49 
et al. 2020). There are questions about how host cells attack coronaviruses and whether 50 
there are other ways to defend against them besides antibodies. The coronavirus–host cell 51 
interactions such as the viral RNA-synthesizing machinery and the evasion of host innate 52 
immune responses are detailed in a review (de Welde et al. 2018). 53 
 Host organisms, including humans, have the ability to detect viral infection as 54 
"non-self-nucleic acid invasion," which is expected to trigger antiviral innate immunity 55 
and suppress viral replication. New coronaviruses have continued to mutate at a high rate 56 
(Gómez-Carballa et al. 2020; Jones and Manrique 2020; Nie et al. 2020; Rochman et al. 57 
2020). Since its emergence, new variants have appeared one after another, and there are 58 
now more than eight in total (Miyake et al. 2021). The types, viral infections, disease 59 
patterns, and mutations of the encoded proteins have not yet been comprehensively 60 
understood. We believe that significant advances in our understanding of this complex 61 
system will be made in the near future. 62 
 The viral helicase (nsp13 in ORF1ab), which plays a central role in the immune 63 
response of host cells, is stably maintained in various strains, and a mutant form was first 64 
isolated in Washington State, USA in February 2020 (Chan et al. 2020). This variant is 65 
present only in a specific genotype (Zhao et al. 2020), which Chan et al. define as 66 
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coevolutionary variant group 4 (CEVg4). In our previous paper (Miyake et al. 2021), we 67 
presented a method to analyze clusters of viral genomes using an autoencoder. Among 68 
the clusters classified by this method, those consisting only of genomes with mutations 69 
in the nsp13 gene on ORF-1ab (C-type SARS -CoV-2 virus genome). Since the other 70 
clusters did not show the said mutation in nsp13, it was considered that the genomes 71 
constituting the clusters had some aggregate characteristics. A closer look at the genomic 72 
variation revealed that the helicase translated and synthesized from nsp13 had double 73 
mutations, P504L and Y541C. 74 
 In silico analysis to evaluate protein-drug interactions suggests that helicase, 75 
the nsp13 product with the double mutation of P504L and Y541C, has an altered shape 76 
of the ATP-binding site (Ugurel et al.). In this paper, along with the analysis of the 77 
clusters, we also examined their relationship to disease during the pandemic. The ration 78 
of wild type (WT)/C SARS-CoV-2 virus ratio based on the weekly number of viruses 79 
classified by the autoencoder and compared the relationship with the number of infected 80 
people and deaths. In the case of the pandemic in Washington State, USA, we found that 81 
the type C virus was dominant in the first two months, and that the virus with wild-type 82 
helicase became overwhelmingly dominant after May 2020. We will also discuss the 83 
involvement of helicases in the current COVID-19 disease.  84 
 85 
Methods 86 
We analyzed the coronavirus epidemic in Washington State, U.S.A. from 2020/2/29 to 87 
2020/7/31. Genome sequence data of novel coronaviruses were collected from the NCBI 88 
Virus database (downloaded on February 26, 2021). Only complete genome sequences 89 
were analyzed (genes with more than two consecutive bases were excluded from the 90 
analysis). Cluster analysis of gene sequences using autoencoders was performed using 91 
the Tensor-Flow library (downgraded from V2.0 to V1.0). computers equipped with 92 
GPUs (NVIDIA Quadoro P-6000) were used. The autoencoder previously classified the 93 
genotypes of the human leukocyte antigen A (HLA-A) gene (Miyake et al. 2018): a 94 
histogram of the frequency of occurrence of 1,024 5-mer words in the SARS-CoV-2 95 
ORF1ab gene was generated using a four-layer autoencoder (1,000,000 epochs with a 96 
batch size of 96) was compressed into a three-dimensional array, which were plotted in 97 
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three-dimensional (3D) space as (x, y, z) coordinates. As a result, 31,050 SARS-CoV-2 98 
ORF1ab genes were classified into eight categories (A1, A2, B1, B2, C, D, E1, and E2 99 
types) (Miyake et al. 2021). Epidemiological data were obtained from the Centers for 100 
Disease Control and Prevention (CDC) database. 101 
 Based on these autoencoder-classified SARS-CoV-2 ORF1ab genes, we 102 
examined time courses of weekly ratios of SARS-CoV-2 viral genomes with wild-type 103 
(WT) helicase (WT helicase genomes belonging to clusters A1, A2, B1, B2, D, E1 and 104 
E2) to those of C-type helicase (C-type genomes belonging to cluster C) that were 105 
collected in Washington State. Note that the C genome was collected only during weeks 106 
4-20 starting from February 1, 2020; the period starting from week 21 was excluded from 107 
the analysis. 108 
 109 
Results 110 
The ORF1ab gene was extracted from the SARS-CoV-2 genome and classified into eight 111 
clusters in three-dimensional space by autoencoder. Among them, C-type was located at 112 
the far end of the cluster spread. It was a small cluster with relatively clear boundaries. 113 
ORF1ab genes of cluster C which have C-type helicase were expanded in March (Fig. 114 
1a) and disappeared after July 3, 2020 (Fig. 1b).  115 
 Helicase is an essential enzyme for viral replication, but a special type of mutant 116 
was found in the United States in February to July, 2020. This mutant is characterized by 117 
the presence of mutations in the nsp13 (helicase) gene of ORF1ab that differ by two bases 118 
from the wild type (C17747T (P504L) and A17858G (Y541C)) (Chan et al., 2020). C-119 
type of ORF1ab was consisted only with the mutant genome. The mutant was not found 120 
in any other clusters. We will refer to this helicase as helicase-C in this paper. Note that 121 
there is also a helicase in which only one of the two mutations was different, but due to 122 
the very small number, it was excluded from this analysis. This cluster (category) 123 
corresponds to the CEVg4 reported by Chan et al. in their combinatorial analysis of 124 
genomic variation (Chan et al., 2020). 125 
 The classification of the clusters as in Fig.1 were plotted against the time axis and 126 
the distance of the 3D data from the center for nine states in the United States (Fig. 2). 127 
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Each cluster was plotted in a different color (A1, red; A2, pink; B1, green; B2, light green; 128 
C, purple; D, orange; E1, blue; E2, light blue). The vertical axis is the distance of the 3D 129 
data used in the autoencoder classification (The nucleotide sequence (29903 nt in the 130 
reference sequence) was compressed into 3 dimensions by autoencoder analysis. The 131 
genomes in the cluster were easily identifies by their positions. Weekly numbers of 132 
helicase-C genomes in the United States, Washington State, and Australia were shown in 133 
Fig. 3.  134 
 The usefulness of the autoencoder classification method is that it can automatically 135 
classify the genomes into clusters without knowing the differences in gene sequences 136 
beforehand, it can handle a huge number of genomes, and it is easy to understand the 137 
temporal variation. In other words, it is a way to spatially represent the "artificial 138 
intelligence recognition" of the full-length sequence of genes. The classification of 139 
clusters depends on where the boundaries are drawn, so there can be some differences in 140 
the number of genes included in some cases. 141 
 The country subcategories of helicase-C SARS-CoV-2 genomes were 1,460 142 
(97.6%) in the United States, 32 (2.1%) in Australia, 2 in the United Kingdom, 1 in Peru, 143 
and 1 in Puerto Rico (country data were taken from NCBI Virus Database). Australia and 144 
less countries were not examined in this study due to small sample size. 145 
In the U.S., helicase-C has been detected in areas where the SARS-CoV-2 146 
outbreak has caused infections, such as California, New York, and Washington State. In 147 
the U.S., the state of Washington had the highest number of database-registered helicase-148 
C genomes at 68.9% (67.4% worldwide) throughout the period of February to June. This 149 
is followed by California (10.5%). Other states were Minnesota (2.8%), Utah (2.8%), 150 
Florida (1.5%), and Massachusetts (1.4%). The portion of the infections and the high 151 
mortality rate in Washington State is remarkable. Washington State was thought to be the 152 
single source of the outbreak and that it spread to other states. 153 
In Washington State, helicase-C SARS-CoV-2 genomes were initially 154 
predominant in the four–eight weeks from February 1, 2020. The WT/C-type helicase 155 
ratio logarithmically increased with a kink at nine weeks when the dominance of WT 156 
helicase genomes was initiated (Fig. 4a). For comparison, weekly numbers of cumulative 157 
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COVID-19 cases and deaths in Washington State (obtained from the Center for Disease 158 
Control and Prevention (CDC) webpage) were shown (Fig. 4b). Weekly numbers of 159 
cumulative cases also logarithmically increased with a kink at nine weeks when the 160 
growth rate markedly decreased. The cumulative number of deaths showed a one-week 161 
lagged kink (week 10) in the logarithmic increase, with a marked decrease in the late 162 
phase. The coincidence of sinks in WT/C helicase ratios, cases, and deaths in Washington 163 
State with a 1-2 week lag suggests that the change in dominance of the SARS-CoV-2 164 
helicase-C genome to the WT helicase-C genome may be responsible for the decrease in 165 
cases and deaths. 166 
 167 
Discussion 168 
In the cluster analysis using the autoencoder, the genome of SARS-CoV-2 with helicase 169 
C could be extracted as one cluster. The other genomes with helicase WT were distributed 170 
in several clusters. These results indicate that the autoencoder can identify the ORF1ab 171 
gene of SARS-CoV with only two mutations in the helicase. Although the genomic 172 
sequence of the helicase is highly conserved in nature, mutations in such a highly 173 
conserved sequence may form specific clusters that are clearly separated by autoencoder 174 
analysis. The ability of autoencoders to extract genomes with significant mutations in 175 
specific gene regions as separate clusters will be beneficial not only for helicases but also 176 
for a variety of other application. 177 
Type-C SARS-CoV-2 virus (hereafter referred to as "type-C virus") was first 178 
discovered in Washington State on February 20 (Chan et al. 2020). in June (after week 179 
21), the number of type-C virus collections has decreased significantly. The last virus was 180 
obtained in Florida on July 2. In the early stages of the pandemic (4-8 weeks counting 181 
from February 1, 2020), type-C virus initially predominated and may have contributed to 182 
the number of COVID-19 cases. By weeks 10-20, the WT helicase genome predominated. 183 
Looking at the semilog plot in Fig. 4, it is understood that the ratio of deaths/infected 184 
cases was considerably larger in the early phase than in the later phase. The inflection 185 
point of the number of infected and deaths was off by almost a week. Assuming a one-186 
week gap between infection and outcome/death, the ratio of deaths/infected may have 187 
been temporarily more than twice as high in the early phase (4-8 weeks) as in the late 188 
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phase.  In the late phase (10-20 weeks), this ratio was consistently less than 6%.  In the 189 
later stages, this ratio was consistently less than 6%. If this large difference is dependent 190 
on the type of virus, it should be fully considered as a preparation for future viral diseases. 191 
The emergence, disappearance, and pathogenesis of type-C virus A detailed analysis of 192 
the mechanisms, mortality dependence, and other factors may be useful as a key to 193 
developing effective treatments and antiviral measures. 194 
All C-type viruses contain a variant of the helicase, helicase-C, which is highly 195 
suspected as a cause of serious disease. Helicase is a protein that unwinds nucleic acids 196 
and is essential for viral genome replication. Adedeji et al. found that helicase activity 197 
was enhanced in the presence of nsp12 in the SARS-CoV epidemic of 2002-2003 198 
(Adedeji et al. .2012). Kindler et al. (Kindler et al. 2017; Ancar et al. 2020) and Deng et 199 
al. (Deng et al. 2017; Deng and Baker 2018) considered the following scheme. The viral 200 
RNA forms a double-stranded structure at the poly-U sequence. If the virus can use RNA-201 
degrading enzymes (EndoU) to cleave its own RNA-poly U sequence, the immune response of 202 
the host cell is inactivated. The structure and interactions of the proteins discussed here are being 203 
studied. Pillon et al. published the four-dimensional protein structure of SARS-CoV-2 nsp15 204 
using Cryo-EM (Pillon et al. 2021). Perry et al. also studied that nsp 15 protein is surrounded by 205 
nsp14, 16, nsp7, 8, and 12 proteins, as well as nsp13 (helicase) using Cryo-EM (Perry et al. 2021). 206 
 Several researchers have pointed out that helicases are important targets for 207 
viral clearance (Gurung 2020; Habtemariam et al. 2020; White et al. 2020). Possible 208 
strategies for drug discovery include the application of existing drugs (Li and De Clercq 209 
2020; Pandey et al. 2020) and RNAi (Liu et al. 2020). Existing compounds that have the 210 
effect of inhibiting the RNA or protein molecules of helicases could also be used. 211 
Computer modeling studies are also underway (Gurung 2020; White et al. 2020). It is 212 
expected that various efforts will be made in drug development. 213 
 Various vaccines have been developed and used now. The biochemical 214 
reactions involved in viral replication in host cells may be used as a countermeasure. If it 215 
is possible to inhibit the intracellular replication mechanism common to various viruses, 216 
it may be an effective countermeasure. 217 
 218 
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(a)                                                                                (b) 318 
 319 
Fig.1. Autoencoder clustered 3D view of ORF1ab gene of SARS-CoV-2 (March and 320 
July 2020). 321 
The number of C-type ORF1ab genes expanded rapidly in March, and new appearances 322 
stopped as of July 3, 2020. (a) ORF1ab gene that appeared in March 2020 (purple). (b) 323 
ORF1ab gene that appeared in July 2020 (yellow-green). Shown in gray as background 324 
is the cluster of ORF1ab genes for the period 19/12/2019-2021/2/16. 325 
  326 
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Fig.2. Evolution of clusters in nine US states. 333 
Eight clusters classified by the autoencoder of the SARS-CoV-2 ORF1ab gene in nine 334 
U.S. states (WA, CA, UT, FL, MA, NY, MN, WI, ME) plotted in different colors by 335 
collection date (A1, red; A2, pink; B1, green; B2, light green; C, purple; D, orange; E1, 336 
blue; E2, light blue).  Cluster C with helicase C appeared in February and disappeared 337 
after July 3, 2020. 338 
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Fig. 3. Transition of C-type SARS-CoV-2 in USA, Washington State and Australia. 342 
Weekly numbers of autoencoder-classified SARS-CoV-2 ORF1ab genes in USA, 343 
Washington State, and Australia are shown by number of weeks from 344 
February/01/2020. 345 
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Fig. 4. Ratio of the numbers of wild-type and C-type helicase SARS-CoV-2 viruses 349 
collected in Washington State in USA. 350 
 351 
(a) The ratio of wild-type/C-type helicase SARS-CoV-2 genomes (green) showed 352 
logarithmic increases with a kink around nine weeks from February 1, 2020 in 353 
Washington State in USA. The first half corresponds to the period when the C-type 354 
helicase viruses rapidly increased, and the second half to the period when the wild-type 355 
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helicase viruses became predominant. Total deaths (orange) and total cases (blue) also 356 
showed logarithmic increases with kinks around ten and nine weeks, respectively. 357 
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